LeVee A, Lin CY, Posadas E, et al. Onco Targets Ther. 2021;14:4819–4832.
The authors have advised there is an error in the author list on page 4819. The author name “Charlos J Rosser” should read “Charles Joel Rosser”.
. 2021 Oct 26;14:5167–5168. doi: 10.2147/OTT.S343977
Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection [Corrigendum]
Received 2021 Oct 12; Accepted 2021 Oct 12; Collection date 2021.
© 2021 LeVee et al.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
PMCID: PMC8556722 PMID: 34729014
This corrects the article "Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection" on page 4819.